Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Investigational New Drugs|February 4, 2018
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cellsAlexandra Canonici, Zulfiqar Qadir, Neil T Conlon, et al.
Investigational New Drugs|August 1, 2018
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancerAlexandra Canonici, Laura Ivers, Neil T Conlon, et al.
Investigational New Drugs|April 23, 2020
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd ALaura Breen, Patricia B Gaule, Alexandra Canonici, et al.
British Journal of Cancer|January 21, 2021
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsNeil T Conlon, Jeffrey J Kooijman, Suzanne J C van Gerwen, et al.
Translational Oncology|August 27, 2024
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivoNeil T Conlon, Sandra Roche, Amira F Mahdi, et al.
Oncogene|December 20, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patientsCharlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, et al.
Plos One|March 15, 2023
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancerSandra Roche, Patricia Gaule, Deirdre Winrow, et al.
British Journal of Cancer|July 28, 2023
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapyNicola Gaynor, Alfonso Blanco, Stephen F Madden, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M Collins, Stephen F Madden, Nicola Gaynor, et al.
Pageof 3